Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection

Masami Nishino1, Yasuyuki Egami1, Shodai Kawanami1

  • 1Division of Cardiology Osaka Rosai Hospital Osaka Japan.

Insights

High uric acid (UA) predicts worse outcomes in heart failure with preserved ejection fraction (HFpEF) patients with hyperuricemia. Lowering UA levels may improve prognosis and reduce mortality or rehospitalization in this population.

Area of Science:

  • Cardiology
  • Nephrology
  • Internal Medicine

Background:

  • An association between uric acid (UA) and cardiovascular diseases, including heart failure (HF), is established.
  • The causal role of UA in HF and its prognostic value in HF with preserved ejection fraction (HFpEF) remain controversial.
  • The impact of lowering UA in patients with hyperuricemia and HFpEF is not well understood.

Purpose of the Study:

  • To investigate the correlation between uric acid (UA) levels and adverse cardiovascular events in patients with hyperuricemia and HFpEF.
  • To evaluate the prognostic value of lowering UA in this patient cohort.
  • To assess whether reducing UA levels impacts all-cause mortality and HF rehospitalization.

Main Methods:

  • Analysis of 464 patients with hyperuricemia (UA >7.0 mg/dL) from the PURSUIT-HFpEF registry.
  • Multivariable Cox regression analysis to determine UA's association with composite endpoints (all-cause mortality and HF rehospitalization).
  • Comparison of outcomes between groups with severe vs. mild hyperuricemia and between those who lowered UA vs. those who did not.

Main Results:

  • UA was an independent determinant of composite death and rehospitalization in patients with hyperuricemia and HFpEF (HR, 1.15).
  • Severe hyperuricemia was associated with significantly higher all-cause mortality compared to mild hyperuricemia (HR, 1.73).
  • Lowering UA levels over one year significantly decreased the incidence of all-cause mortality (HR, 1.71), with a trend towards increased urate-lowering therapy use.

Conclusions:

  • Uric acid is a significant predictor of composite death and HF rehospitalization in patients with hyperuricemia and HFpEF.
  • Lowering uric acid levels, potentially through urate-lowering therapy, may offer a therapeutic strategy to improve prognosis in this population.
  • Further research is warranted to confirm the benefits of UA reduction in HFpEF management.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
459
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
489
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
25
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26